CY1121347T1 - Πρωτεϊνη συντηξης - Google Patents

Πρωτεϊνη συντηξης

Info

Publication number
CY1121347T1
CY1121347T1 CY20191100281T CY191100281T CY1121347T1 CY 1121347 T1 CY1121347 T1 CY 1121347T1 CY 20191100281 T CY20191100281 T CY 20191100281T CY 191100281 T CY191100281 T CY 191100281T CY 1121347 T1 CY1121347 T1 CY 1121347T1
Authority
CY
Cyprus
Prior art keywords
fusion protein
p75ntr
nbp
moiety
pain
Prior art date
Application number
CY20191100281T
Other languages
English (en)
Inventor
Simon Westbrook
Original Assignee
Levicept Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levicept Ltd. filed Critical Levicept Ltd.
Publication of CY1121347T1 publication Critical patent/CY1121347T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2807Headache; Migraine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2842Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε πρωτεΐνη σύντηξης p75NTR πρωτεΐνης σύνδεσης νευροτροφίνης (NBP)-Fc που περιλαμβάνει τμήμα p75NTR(NBP) και τμήμα ανοσοσφαιρίνης. Σε συγκεκριμένες εφαρμογές, η πρωτεΐνη σύντηξης p75NTR(NBP)-Fc είναι για χρήση στην θεραπεία πόνου ή/και συμπτώματος πόνου.
CY20191100281T 2013-09-18 2019-03-08 Πρωτεϊνη συντηξης CY1121347T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1316592.3A GB201316592D0 (en) 2013-09-18 2013-09-18 Fusion protein
PCT/GB2014/052833 WO2015040398A1 (en) 2013-09-18 2014-09-18 Fusion protein

Publications (1)

Publication Number Publication Date
CY1121347T1 true CY1121347T1 (el) 2020-05-29

Family

ID=49552839

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100281T CY1121347T1 (el) 2013-09-18 2019-03-08 Πρωτεϊνη συντηξης

Country Status (25)

Country Link
US (3) US9873728B2 (el)
EP (1) EP3046934B1 (el)
JP (3) JP6681834B2 (el)
KR (1) KR102205633B1 (el)
CN (1) CN105873943B (el)
AU (1) AU2014322842B2 (el)
CA (1) CA2924410C (el)
CY (1) CY1121347T1 (el)
DK (1) DK3046934T3 (el)
EA (1) EA037416B1 (el)
ES (1) ES2714694T3 (el)
GB (1) GB201316592D0 (el)
HR (1) HRP20190434T1 (el)
HU (1) HUE043273T2 (el)
IL (1) IL244588B (el)
LT (1) LT3046934T (el)
MX (1) MX2016003530A (el)
NZ (1) NZ718044A (el)
PL (1) PL3046934T3 (el)
PT (1) PT3046934T (el)
RS (1) RS58463B1 (el)
SG (1) SG11201602068QA (el)
SI (1) SI3046934T1 (el)
TR (1) TR201903490T4 (el)
WO (1) WO2015040398A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201705725XA (en) 2012-03-14 2017-08-30 Levicept Ltd Therapeutic use of p75ntr neurotrophin binding protein
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) * 2015-03-19 2015-05-06 Levicept Ltd Fusion protein
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN113456799A (zh) * 2020-12-25 2021-10-01 苏州澳宗生物科技有限公司 一种p75ECD在制备用于调节疼痛的药物中的应用
CN112851794B (zh) * 2021-02-04 2023-05-23 苏州铂维生物科技有限公司 一种基于cd271的抗原表位及其应用
WO2023067358A1 (en) * 2021-10-21 2023-04-27 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
US11608371B1 (en) 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ, インコーポレイテッド IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
US20090232808A1 (en) * 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
JPWO2007026567A1 (ja) 2005-08-30 2009-03-05 国立大学法人 千葉大学 p75NTR阻害剤を有効成分として含有する鎮痛剤
WO2007070983A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
GB0717985D0 (en) * 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
US20100061981A1 (en) 2008-08-15 2010-03-11 The Salk Institute For Biological Studies p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING
EP2413962A1 (en) * 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
CN102656266B (zh) * 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
BR112012013330A2 (pt) 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
CN102233128B (zh) * 2010-11-26 2013-04-17 王延江 一种p75NTR-ECD在防治阿尔茨海默病药物中应用
ITRM20110024A1 (it) * 2011-01-24 2012-07-25 Consiglio Nazionale Ricerche Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche.
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Fc融合蛋白及其用途
CN102586313A (zh) 2012-03-05 2012-07-18 中国人民解放军第三军医大学野战外科研究所 p75NTR-ED-Fc融合蛋白的制备方法及其在损伤中枢神经再生与功能恢复中的应用
SG10201705725XA (en) * 2012-03-14 2017-08-30 Levicept Ltd Therapeutic use of p75ntr neurotrophin binding protein
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein

Also Published As

Publication number Publication date
TR201903490T4 (tr) 2019-03-21
JP2016531590A (ja) 2016-10-13
US10988526B2 (en) 2021-04-27
GB201316592D0 (en) 2013-10-30
AU2014322842A1 (en) 2016-04-07
JP2020062011A (ja) 2020-04-23
EA201690469A1 (ru) 2016-12-30
JP7357088B2 (ja) 2023-10-05
CN105873943B (zh) 2023-04-07
PT3046934T (pt) 2019-03-25
SI3046934T1 (sl) 2019-04-30
PL3046934T3 (pl) 2019-05-31
CA2924410C (en) 2023-01-24
CA2924410A1 (en) 2015-03-26
US20160222082A1 (en) 2016-08-04
US9873728B2 (en) 2018-01-23
IL244588B (en) 2019-12-31
HRP20190434T1 (hr) 2019-04-19
JP2022068253A (ja) 2022-05-09
EP3046934B1 (en) 2018-12-12
HUE043273T2 (hu) 2019-08-28
RS58463B1 (sr) 2019-04-30
DK3046934T3 (en) 2019-04-08
IL244588A0 (en) 2016-04-21
US20210238256A1 (en) 2021-08-05
BR112016006113A2 (pt) 2017-09-26
SG11201602068QA (en) 2016-04-28
US20180273603A1 (en) 2018-09-27
ES2714694T3 (es) 2019-05-29
CN105873943A (zh) 2016-08-17
MX2016003530A (es) 2016-10-13
EP3046934A1 (en) 2016-07-27
EA037416B1 (ru) 2021-03-25
LT3046934T (lt) 2019-03-25
AU2014322842B2 (en) 2018-08-16
JP6681834B2 (ja) 2020-04-15
NZ718044A (en) 2020-07-31
KR20160058872A (ko) 2016-05-25
WO2015040398A1 (en) 2015-03-26
KR102205633B1 (ko) 2021-01-20

Similar Documents

Publication Publication Date Title
CY1121347T1 (el) Πρωτεϊνη συντηξης
CY1119213T1 (el) Πρωτεϊνη p75ntr συνδεσης νευροτροφινης για θεραπευτικη χρηση
CY1122308T1 (el) St2l ανταγωνιστες και μεθοδοι χρησης
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1120177T1 (el) Φλαγκελλινη roseburia και ανοσορυθμιση
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
CY1121637T1 (el) Αντι-dkk-1 αντισωματα
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
EA201692039A1 (ru) ИММУНОГЛОБУЛИНЫ, СВЯЗЫВАЮЩИЕ ЧЕЛОВЕЧЕСКИЕ Vγ9Vδ2 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ
EA201992712A2 (ru) Трициклические гетероциклы как ингибиторы белков бэт
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
CL2015003126A1 (es) Anticuerpos modificados de unión a fcrn humano y métodos de utilización.
EA201690314A1 (ru) Анти-garp-белок и его применения
EA201591973A1 (ru) Антитела человека, связывающиеся с g-белком rsv
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
DOP2013000047A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
EA201690898A1 (ru) Способы лечения таупатии